enGene Inc. Warrants

0.68
0.06 (9.61%)
At close: Mar 28, 2025, 12:11 PM
0.68
-0.66%
After-hours: Mar 28, 2025, 04:02 PM EDT

Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

The company was founded in 2023 and is based in Saint-Laurent, Canada.

enGene Inc. Warrants
enGene  Inc. Warrants logo
Country CA
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 56
CEO Ronald H. W. Cooper

Contact Details

Address:
No Address available
No city data available,
CA
Website n/a

Stock Details

Ticker Symbol ENGNW
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001980845
CUSIP Number n/a
ISIN Number n/a
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Ronald H. W. Cooper President, Chief Executive Officer & Director
David Ryan Daws Chief Financial Officer & Head of Business Development
Joan Connolly Chief Technology Officer
Lee G. Giguere Chief Legal Officer & Corporate Secretary
Dr. Alexander Nichols Ph.D. Chief Strategy & Operations Officer
Dr. Anthony T. Cheung Ph.D. Co-Founder & Chief Scientific Officer
Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A. Chief Medical Officer
John C. Brown D.Sc., FRSC, Ph.D. Co-Founder and Member of Scientific Advisory Board
Matthew Boyd Senior Vice President of Regulatory Affairs
Tara Place M.B.A. Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 10, 2025 S-8 Filing
Mar 10, 2025 10-Q Quarterly Report
Mar 10, 2025 8-K Current Report
Feb 20, 2025 10-K/A [Amend] Annual Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 12, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 31, 2025 4 Filing